Libmeldy: ‘Significant Discount’ For World’s Most Expensive Drug Secures English Funding
US Filing Planned In Late 2022 Or Early 2023
Executive Summary
Orchard Therapeutics has agreed to lower the price of its £2.8m gene therapy for children with metachromatic leukodystrophy following negotiations with the National Health Service. Meanwhile, reimbursement efforts in the rest of Europe are also gaining speed and a US filing is planned.